13.04.2017
Biotest AG DE0005227235
DGAP-News: Biotest AG: Biotest informs about limited availability of albumin
DGAP-News: Biotest AG / Key word(s): Development of Sales
Biotest AG: Biotest informs about limited availability of albumin
13.04.2017 / 17:37
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
/
PRESS RELEASE
Biotest informs about limited availability of albumin
- Due to an equipment failure the availability of albumin is currently
limited
- Consequences on sales and annual results are currently not assessable
Dreieich, 13 April 2017 Today, Biotest has started to inform its customers
about an expected albumin supply shortage within the coming months. This is
due to an equipment failure in the production of an albumin intermediate.
The equipment failure has already been fixed.
In accordance with the relevant authorities, Biotest decided today that all
batches which have been produced in the affected equipment and have already
been supplied, must not be used until the issue is clarified.
Additional necessary analyses are currently conducted. We expect results
within the next four weeks. Biotest will take further steps on the basis of
these analysis data. The impact on sales and annual results for the Biotest
Group are only assessable afterwards.
About Human Albumin
Albumin is used in particular in intensive care medicine and acute care.
Patients with extensive blood or fluid loss, due to burns among other
things, have too little of the important proteins in their blood. This
protein loss is compensated by administering Albumin. Albumin is also used
for volume replacement in cases of blood poisoning. Unlike synthetically
manufactured drugs, Albumin produced from human plasma offers particularly
good tolerability. It is also the most important protein carrier in the
blood for binding and removing (harmful) substances from the vascular
system.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.
---------------------------------------------------------------------------
13.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
564977 13.04.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3